A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 313 participants.
Also called NCT02072226
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 313 participants
- Sponsor
- Registry
-
NCT02072226
-
- Other papers using this trial's data
- Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Terminated
Technical summary
Registry record NCT02072226. Randomized; double masking; primary purpose treatment. Start 2014-05-31 (actual); primary completion 2017-03-22 (actual). Results posted on 2018-07-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke
- Acronym
- PRISMS
- Condition
- Stroke
- Intervention (Drug)
- Alteplase
- Intervention (Drug)
- Alteplase Placebo
- Intervention (Drug)
- Aspirin
- Intervention (Drug)
- Aspirin Placebo
- Lead sponsor
- Genentech, Inc.
Record details
- Record id
cardio:ct-nct02072226- Content hash
89c0c06764a41d2a4ed08f29450f79ff678349244cf589da9118a73aac40e855